Mucinous colorectal adenocarcinoma: clinical pathology and treatment options

Wiley - Tập 39 Số 1 - Trang 1-13 - 2019
Cong Luo1,2, Shuyi Cen1,3, Guojun Ding4, Wei Wang5
1Cong Luo and Shuyi Cen have contributed equally to this work and so served both as the first author
2Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, 310022 Zhejiang, P. R. China
3School of Medicine, Zhejiang University, Hangzhou, 310058 Zhejiang, P. R. China
4Department of Radiotherapy, Zhejiang Cancer Hospital, Hangzhou, 310022 Zhejiang, P. R. China
5Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, 310022 Zhejiang, P. R. China

Tóm tắt

AbstractMucinous colorectal adenocarcinoma is a distinct subtype of colorectal cancer (CRC) characterized by the presence of abundant extracellular mucin which accounts for at least 50% of the tumor volume. Mucinous colorectal adenocarcinoma is found in 10%–20% of CRC patients and occurs more commonly in female and younger patients. Moreover, mucinous colorectal adenocarcinoma is more frequently located in the proximal colon and diagnosed at an advanced stage. Based on its molecular context, mucinous colorectal adenocarcinoma is associated with the overexpression of mucin 2 (MUC2) and mucin 5AC (MUC5AC) proteins. At the same time, it shows higher mutation rates in the fundamental genes of the RAS/MAPK and PI3K/Akt/mTOR pathways. Mucinous colorectal adenocarcinoma also shows higher rates of microsatellite instability (MSI) than non‐mucinous colorectal adenocarcinoma which might correlate it with Lynch syndrome and the CpG island methylator phenotype. The prognosis of mucinous colorectal adenocarcinoma as to non‐mucinous colorectal adenocarcinoma is debatable. Further, the impaired responses of mucinous colorectal adenocarcinoma to palliative or adjuvant chemotherapy warrant more studies to be performed for a specialized treatment for these patients. In this review, we discuss the molecular background and histopathology of mucinous colorectal adenocarcinoma, and provide an update on its prognosis and therapeutics from recent literatures.

Từ khóa


Tài liệu tham khảo

10.1055/s‐0029‐1242458

Bosman FT, 2010, WHO classification of tumours of the digestive system

10.1038/sj.bjc.6602330

10.1245/s10434‐007‐9757‐1

10.1245/s10434‐014‐3706‐6

10.1002/path.2181

10.1136/jclinpath‐2011‐200340

10.1038/sj.bjc.6604955

10.1093/annonc/mdt378

10.1016/j.surg.2014.01.011

10.1016/j.mayocp.2013.09.006

Okuno M, 1988, Mucinous colorectal carcinoma: clinical pathology and prognosis, Am Surg., 54, 681

10.5946/ce.2012.45.1.103

10.1245/s10434‐013‐3169‐1

10.1007/BF02050301

10.3748/wjg.v19.i25.3957

10.1177/44.10.8813081

10.1002/cjp2.1

10.1038/bjc.1995.514

Gruia C, 2011, Synchronous carcinoma of the ascending colon and caecum, Rom J Morphol Embryol, 52, 1369

10.1002/1096‐9098(200010)75:2<103::AID‐JSO6>3.0.CO;2‐C

10.1159/000487710

10.1093/annonc/mdr062

10.1038/bjc.2016.57

NumataM ShiozawaM WatanabeT TamagawaH YamamotoN MorinagaS et al.The clinicopathological features of colorectal mucinous adenocarcinoma and a therapeutic strategy for the disease.World J Surg Oncol.2012;10.1186/1477‐7819‐10‐1093407705

10.1245/s10434‐014‐4159‐7

10.1245/s10434‐012‐2321‐7

10.1093/annonc/mdt591

10.1002/ijc.28981

10.1007/s00428‐016‐1970‐5

10.1038/nrc2761

10.1093/carcin/bgw120

10.1006/geno.1996.0637

10.1007/s11670‐012‐0190‐z

10.1038/nrclinonc.2015.140

10.1080/00015458.2013.11680951

10.1046/j.1440‐1827.2002.01369.x

10.1002/ijc.23225

10.1007/s00428‐014‐1638‐y

10.1053/j.gastro.2009.12.064

10.3349/ymj.2015.56.1.175

10.1038/modpathol.2015.159

10.1016/j.dld.2012.10.006

10.1007/s11864‐015‐0348‐2

10.1111/his.12055

10.1038/nrgastro.2011.173

10.1038/modpathol.2012.240

10.1002/jso.20438

10.1097/PAS.0b013e31824430d7

10.1038/bjc.2011.19

10.1056/NEJMc0904160

10.3389/fonc.2013.00281

10.1002/ijc.28183

Takahashi Y, 1995, Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer, Can Res., 55, 3964

10.3816/CCC.2004.n.025

Berk V, 2015, Predictive significance of VEGF and HIF‐1alpha expression in patients with metastatic colorectal cancer receiving chemotherapy combinations with bevacizumab, APJCP., 16, 6149

10.1007/s10151‐013‐1099‐3

10.1097/00004728‐200301000‐00010

Fu Z, 2012, mucinous adenocarcinoma of the colon pathological characters and CT image analysis, Chin J Mod Drug Appl., 04, 24

10.1179/1973947812y.0000000013

10.1097/dcr.0000000000000635

10.1002/jmri.23952

10.1093/annonc/mdi244

10.1016/j.ejca.2011.12.004

10.1097/md.0000000000000658

10.1111/j.1463‐1318.2005.00934.x

10.3978/j.issn.2078‐6891.2014.020

10.1016/j.ejso.2013.11.005

10.1245/s10434‐014‐4339‐5

Liu Z, 2016, Comparison of FOLFOX and FOLFIRI adjuvant chemotherapy regimens in the treatment of colorectal mucinous adenocarcinoma, Chin J Colorec Dis (Electronic Edition), 5, 159

10.1093/annonc/mdx175

VenookAP NiedzwieckiD InnocentiF FruthB GreeneC O'NeilBH et al.Impact of primary (1 degrees) tumor location on overall survival (OS) and progression‐free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB/SWOG 80405 (Alliance).J Clin Oncol.2016;10.1200/jco.2016.34.15_suppl.35045012711

10.1016/j.clcc.2015.12.006

10.1001/jama.2017.7105

10.3892/or.2012.1626

10.1158/1078‐0432.ccr‐13‐0489

10.1097/IGC.0b013e31829f17c9

10.1016/j.ygyno.2016.10.021

Liu H, 2015, Addition of bevacizumab to neoadjuvant chemotherapy for stage IV ovarian serous adenocarcinoma with multiple lymph node metastases: a case report, Eur J Gynaecol Oncol., 36, 341

10.1186/s12885‐015‐1908‐3

10.1245/s10434‐013‐3061‐z

10.1055/s‐0035‐1564433

10.1016/j.ejpb.2015.01.008

10.1016/j.ejpb.2017.09.016

10.1016/j.ijpharm.2013.05.040

10.4155/tde‐2015‐0002

Loftsson T, 2012, Drug permeation through biomembranes: cyclodextrins and the unstirred water layer, Pharmazie, 67, 363

10.1038/nmat2347

10.1056/NEJMoa1200690

10.1056/NEJMoa1500596

10.1158/2159‐8290.cd‐14‐1397

10.1016/S1470‐2045(17)30422‐9

10.1038/bjc.2016.211

10.1200/JCO.2017.76.9901

10.1093/annonc/mdy424.019

10.1038/s41591‐018‐0053‐3

10.1200/jco.2017.35.4_suppl.673

10.1007/s10350‐007‐9026‐1

10.1245/s10434‐011‐1612‐8

Thông tin
Thông tin xuất bản

Wiley

Tập 39 Số 1

1-13

Thông tin tác giả